Transthyretin (TTR)

Assets acting on this target.

Class
Anti-transthyretin monoclonal antibody

Transthyretin (TTR) is a protein made mainly in the liver that circulates in blood, transporting thyroid hormone and vitamin A-binding protein. Normally, four TTR molecules assemble into a stable tetramer. In some people, this tetramer can dissociate, either because of an inherited mutation or simply with aging, and the resulting misfolded protein units aggregate into amyloid fibrils. These fibrils deposit in tissues such as the heart and peripheral nerves, causing transthyretin amyloidosis, a disease that presents as restrictive cardiomyopathy or progressive polyneuropathy. Existing therapeutic strategies include small molecules that stabilize the tetramer and gene-silencing agents that reduce TTR production in the liver. Anti-TTR monoclonal antibodies represent a distinct approach: rather than preventing new amyloid formation, they are designed to bind amyloid deposits already present in tissue and flag them for clearance by the immune system. This matters because stabilizers and silencers slow disease progression but do little to remove amyloid that has already accumulated, whereas an antibody-mediated clearance mechanism aims to reduce existing tissue burden, potentially offering benefit even in patients with established organ damage.

By indication

Transthyretin (TTR) drugs compared

9 drugs, stage by indication
9 drugs acting on Transthyretin (TTR): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
AcoramidisAttrubyAlexion Pharmaceuticals, Inc. (subsidiary of AstraZeneca), Bayer, BridgeBio Pharmasmall moleculeApprovedApproved in Transthyretin Amyloidosis with Cardiomyopathy
EplontersenWainuaAstraZeneca, Ionis PharmaceuticalsantisenseApprovedApproved in Transthyretin Amyloidosis with Polyneuropathy; Phase 3 in Transthyretin Amyloidosis with Cardiomyopathy
PatisiranONPATTROAlnylam PharmaceuticalsRNAiApprovedApproved in Transthyretin Amyloidosis with Polyneuropathy
VutrisiranAMVUTTRAAlnylam PharmaceuticalsRNAiApprovedApproved in Transthyretin Amyloidosis with Cardiomyopathy; Approved in Transthyretin Amyloidosis with Polyneuropathy
InotersenTegsediIonis Pharmaceuticals, Swedish Orphan Biovitrum AB (publ)antisenseUS approval withdrawnUS approval withdrawn in Transthyretin Amyloidosis with Polyneuropathy
CliramitugAstraZenecamonoclonal antibodyPhase 3Phase 3 in Transthyretin Amyloidosis with Cardiomyopathy
CoramitugNovo Nordiskmonoclonal antibodyPhase 3Phase 3 in Heart Failure
Nexiguran ziclumeranRegeneron Pharmaceuticalsgene editing (CRISPR)Phase 3Phase 3 in Transthyretin Amyloidosis with Cardiomyopathy
NucresiranAlnylam PharmaceuticalsRNAiPhase 3Phase 3 in Transthyretin Amyloidosis with Cardiomyopathy; Phase 3 in Transthyretin Amyloidosis with Polyneuropathy

← all mechanisms